BioBoss podcast host John Simboli reflects on Seasons 1-6 and invites listeners to Season 7 starting in January 2026

Michael Cloonan, CEO of Sionna Therapeutics, shares his insights about leadership in biopharma and how Sionna is working to restore the cystic fibrosis transmembrane conductance regulator for people living with cystic fibrosis.

Erik van den Berg, CEO of Memo Therapeutics, shares his insights about leadership in biopharma and how Memo is working to develop antibodies to transform the lives of patients with viral infections and cancer.

Bruce Leuchter, CEO of Neurvati Neurosciences, shares his insights about leadership in biopharma and how Neurvati is working to advance drugs with the potential to improve the health and lives of people living with neurological and psychiatric disorders.

Todd Harris, CEO of Tyra Biosciences, shares his insights about leadership in biopharma and how Tyra is working to develop precision medicines that target large fibroblast growth factor receptor biology.

Eduardo Bravo, CEO of Citryll, shares his insights about leadership in biopharma and how Citryll is working to transform the approach to treating immune mediated inflammatory diseases.

Abbas Kazimi, CEO of Nimbus Therapeutics, shares his insights about leadership in biopharma and how Nimbus is working to design and develop small molecule medicines capable of improving patients' lives.

Derek Adams, CEO of Stellular Bio, shares his insights about leadership in biopharma and how Stellular Bio is working to expand the reach of regenerative medicine.

Geoffrey Dow, CEO of 60 Degrees Pharmaceuticals, shares his insights about leadership in biopharma and how 60 Degrees Pharmaceuticals is working to develop vital medicines to treat and prevent infectious diseases.

Jorge Santos da Silva, co-founder and CEO of MoonLake Immunotherapeutics, shares his insights about leadership in biopharma and how MoonLake Immunotherapeutics is working to develop life changing therapies for people living with serious inflammatory diseases.